States move to ban “tianeptine gas station heroin” as doctors warn of deadly opioid-like risks
Tianeptine, nicknamed “gas station heroin,” is an unapproved opioid-like substance sold illegally in convenience stores, gas stations and online across the U.S., prompting urgent health warnings about addiction, respiratory depression, coma and fatal overdoses among unsuspecting users.
- Unapproved and dangerous: Tianeptine is not FDA-approved in the United States and can act like a potent opioid at high doses.
- Widespread sales: Products under names such as Tianaa, ZaZa, Neptune’s Fix, Pegasus and TD Red have appeared at gas stations, vape shops and online.
- State and federal response: At least 10–14 states have moved to schedule or ban tianeptine; federal lawmakers and the FDA have issued alerts and urged removals.
What is tianeptine — and why is it called “gas station heroin”?
Tianeptine is a tricyclic antidepressant prescribed in some European, Asian and South American countries at low doses to treat depression and anxiety; however, it has never been approved by the U.S. Food and Drug Administration for any use in the United States. For background, see the NCBI research news on tianeptine.
In the U.S., some companies illegally market tianeptine as a dietary supplement, nootropic or treatment for pain, mood, anxiety or opioid withdrawal — a practice flagged by the FDA consumer alert and summarized by the Mayo Clinic overview.
At low recreational doses some users report a serotonin-associated euphoria; at higher doses, tianeptine binds mu-opioid receptors and can be more potent than morphine, producing opioid-like effects, tolerance and rapid addiction. For pharmacology and clinical notes see the NCBI research news and a clinical summary from VCU Health.
Health risks, clinical reports and hospital clusters
Emergency departments and poison control centers have recorded rising reports tied to tianeptine use. Regional hospitals and poison centers, including Virginia’s, have documented cases needing intensive care. New Jersey reported a 2024 cluster of nine critical illnesses linked to a product called Neptune’s Fix, which also contained synthetic cannabinoids; see the New Jersey health alert and the FDA consumer alert.
Reported adverse effects include agitation, confusion, sedation, nausea, vomiting, sweating, rapid heart rate, high blood pressure, seizures, prolonged QT interval, respiratory depression, coma and death — risks that increase sharply when mixed with alcohol, prescription opioids or other drugs (see Mayo Clinic and the FDA).
Clinician note: Cases have required ICU care and targeted investigations; routine panels often miss tianeptine, complicating diagnosis and delaying appropriate care.
Why routine testing can miss it
Most standard drug screens do not detect tianeptine, which can obscure causes of unexplained overdoses or severe sedation. Poison control centers urge clinicians to ask about over-the-counter and off-label supplements when patients present with opioid-like symptoms but test negative on routine panels — guidance highlighted in the FDA consumer alert.
Legal actions and state bans
By 2025 at least 10–14 states have moved to ban or classify tianeptine as a Schedule I controlled substance. Connecticut recently added tianeptine to its schedule alongside kratom, nitazenes and other substances to take effect Wednesday; officials said the action aims to protect youth and people with substance-use disorders (state press releases; see also VCU Health).
On the federal level, lawmakers and clinicians are pushing for clearer regulation. Representative Frank Pallone (D-N.J.) has urged convenience store associations and retailers to enforce recalls and remove dangerous products from shelves after clusters linked to tainted items; read the Rep. Pallone press release. The FDA has issued consumer alerts urging removal of these products and warning the public about cases among young people.
Voices from clinicians and officials
Connecticut Lt. Gov. Susan Bysiewicz said the schedule change is necessary to combat addiction, noting false marketing and candy-like flavoring make products especially dangerous for youth and those in recovery.
Dr. Robert Schwaner, an emergency physician at Stony Brook, described the drug’s dose-dependent shift from serotonin activity to dangerous mu-opioid receptor stimulation and warned that significant opioid activity can lead to respiratory failure and cardiac arrest. He supports national regulation given tianeptine’s addictive profile.
Regulatory warnings and consumer alerts
The FDA has repeatedly warned consumers and clinicians about tianeptine in products marketed as supplements or mood enhancers. State health departments, including New Jersey’s, have issued health alerts and tracked clusters; clinicians can consult local poison control centers for testing guidance (see New Jersey health alert).
Poison control centers advise that suspected exposures causing heavy sedation or slowed breathing require immediate emergency care; naloxone may help if opioid effects are present.
Implications for the United States
Economic: Convenience stores, gas stations and small retailers face decisions about product removal, supplier vetting and recalls. State bans and enforcement could reduce revenue from novelty supplements but also shield businesses from legal risk if products cause harm (see FDA consumer alert).
Political: The push to ban tianeptine shows bipartisan concern about unregulated supplements sold at retail outlets. Lawmakers must balance public safety with questions about federal versus state scheduling authority; see the Rep. Pallone press release.
Social and cultural: Flavored or candy-like products appeal to youth and may drive relapse among people in recovery, particularly in rural communities where the corner store is a local hub. Public health outreach should emphasize protecting children and supporting recovery programs.
Practical applications for residents and retailers
- Check pantries and medicine cabinets for products labeled as mood enhancers, nootropics or supplements that list unfamiliar ingredients.
- Parents should talk to children about never taking unapproved pills or powders.
- Retailers should remove suspect products immediately and report concerns to local health departments.
- Clinicians and first responders should consider tianeptine in unexplained opioid-like presentations even when standard drug screens are negative.
Resources and help
If you or someone you know is struggling with substance misuse, contact SAMHSA’s National Helpline at 1-800-662-HELP (4357) for free, confidential support 24/7 in English and Spanish. Clinicians can consult local poison control centers and state health alerts for the latest testing guidance (see the New Jersey health alert).
Selected sources and further reading
- FDA consumer alert on tianeptine
- Mayo Clinic overview of tianeptine misuse
- VCU Health summary on risks and reports
- NCBI research news and pharmacology
- New Jersey health alert (Neptune’s Fix cluster)
- Congressional press release urging recalls and retailer action
- SAMHSA national helpline
Reporting supported by Times Media Service.
